RU2012109383A - Кристаллические структуры фрагментов нейропилина и комплексов нейропилин-антитело - Google Patents

Кристаллические структуры фрагментов нейропилина и комплексов нейропилин-антитело Download PDF

Info

Publication number
RU2012109383A
RU2012109383A RU2012109383/10A RU2012109383A RU2012109383A RU 2012109383 A RU2012109383 A RU 2012109383A RU 2012109383/10 A RU2012109383/10 A RU 2012109383/10A RU 2012109383 A RU2012109383 A RU 2012109383A RU 2012109383 A RU2012109383 A RU 2012109383A
Authority
RU
Russia
Prior art keywords
crystal
crystal according
nrp2
diffracts
fab fragment
Prior art date
Application number
RU2012109383/10A
Other languages
English (en)
Inventor
Брент А. ЭППЛТОН
Кристиан ВИСМАНН
Янь У
Original Assignee
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженентек, Инк. filed Critical Дженентек, Инк.
Publication of RU2012109383A publication Critical patent/RU2012109383A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)

Abstract

1. Кристалл комплекса, образованного фрагментом Nrp2и Fab-фрагментом антитела против panNrp, который подавляет связывание семафорина с Nrp2, где указанный кристалл дифрагирует рентгеновское излучение, производя картину дифракции, отображающую трехмерную структуру указанного комплекса, имеющего приблизительно следующие параметры элементарной ячейки: a=148 Å, b=106 Å, c=92,4 Å и пространственную группу C2.2. Кристалл по п.1, который дифрагирует рентгеновское излучение до разрешения 2,75Å.3. Кристалл по п.1, где указанный Fab-фрагмент содержится в SEQIDNO: 10.4. Композиция, содержащая кристалл по п.1.5. Кристалл комплекса, образованного фрагментом Nrp2и Fab-фрагментом антитела против panNrp, который подавляет связывание семафорина с Nrp2, где указанный кристалл дифрагирует рентгеновское излучение, производя картину дифракции, отображающую трехмерную структуру указанного комплекса, имеющего приблизительно следующие параметры элементарной ячейки: a=121 Å, b=121 Å, c=203 Å и пространственную группу P321.6. Кристалл по п.5, который дифрагирует рентгеновское излучение до разрешения 3,1Å.7. Кристалл по п.5, где указанный Fab-фрагмент содержится в SEQIDNO: 10.8. Композиция, содержащая кристалл по п.5.9. Кристалл по п.1 или 5 для применения в скринирующем анализе для идентификации антагониста семафорина.

Claims (9)

1. Кристалл комплекса, образованного фрагментом Nrp2a1a2b1b2 и Fab-фрагментом антитела против panNrpA, который подавляет связывание семафорина с Nrp2, где указанный кристалл дифрагирует рентгеновское излучение, производя картину дифракции, отображающую трехмерную структуру указанного комплекса, имеющего приблизительно следующие параметры элементарной ячейки: a=148 Å, b=106 Å, c=92,4 Å и пространственную группу C2.
2. Кристалл по п.1, который дифрагирует рентгеновское излучение до разрешения 2,75Å.
3. Кристалл по п.1, где указанный Fab-фрагмент содержится в SEQIDNO: 10.
4. Композиция, содержащая кристалл по п.1.
5. Кристалл комплекса, образованного фрагментом Nrp2a1a2b1b2 и Fab-фрагментом антитела против panNrpA, который подавляет связывание семафорина с Nrp2, где указанный кристалл дифрагирует рентгеновское излучение, производя картину дифракции, отображающую трехмерную структуру указанного комплекса, имеющего приблизительно следующие параметры элементарной ячейки: a=121 Å, b=121 Å, c=203 Å и пространственную группу P3221.
6. Кристалл по п.5, который дифрагирует рентгеновское излучение до разрешения 3,1Å.
7. Кристалл по п.5, где указанный Fab-фрагмент содержится в SEQIDNO: 10.
8. Композиция, содержащая кристалл по п.5.
9. Кристалл по п.1 или 5 для применения в скринирующем анализе для идентификации антагониста семафорина.
RU2012109383/10A 2007-05-12 2012-03-12 Кристаллические структуры фрагментов нейропилина и комплексов нейропилин-антитело RU2012109383A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
USPCT/US2007/069185 2007-05-12
PCT/US2007/069185 WO2008143666A2 (en) 2007-05-17 2007-05-17 Crystal structures of neuropilin fragments and neuropilin-antibody complexes

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2009146823/10A Division RU2454427C2 (ru) 2007-05-17 2007-05-17 АНТИТЕЛО ПРОТИВ panNrpA (ВАРИАНТЫ)

Publications (1)

Publication Number Publication Date
RU2012109383A true RU2012109383A (ru) 2013-09-20

Family

ID=38963109

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012109383/10A RU2012109383A (ru) 2007-05-12 2012-03-12 Кристаллические структуры фрагментов нейропилина и комплексов нейропилин-антитело

Country Status (14)

Country Link
US (2) US8318163B2 (ru)
EP (1) EP2158215B1 (ru)
JP (1) JP2010530359A (ru)
KR (1) KR101523788B1 (ru)
CN (1) CN101743253B (ru)
AU (1) AU2007353779B2 (ru)
BR (1) BRPI0721707A2 (ru)
CA (1) CA2687556A1 (ru)
ES (1) ES2541051T3 (ru)
HK (1) HK1144580A1 (ru)
IL (1) IL201983A (ru)
MX (1) MX2009012282A (ru)
RU (1) RU2012109383A (ru)
WO (1) WO2008143666A2 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
JP5940061B2 (ja) * 2010-06-18 2016-06-29 ジェネンテック， インコーポレイテッド 抗ａｘｌ抗体及び使用方法
DK2686020T3 (en) 2011-03-17 2017-05-01 Univ Birmingham REDIRECTED IMMUNTERY
EP3838923B1 (en) 2012-08-24 2024-05-01 The Regents of The University of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
CN103992376B (zh) * 2013-02-18 2017-05-17 上海市第一人民医院 一种抑制新生血管的小肽及其应用
CN103992377B (zh) * 2013-02-18 2017-05-17 上海市第一人民医院 一种抑制新生血管的小肽及其应用
DK3460054T3 (da) 2013-03-15 2021-01-18 Atyr Pharma Inc Histidyl-tRNA-syntetase-Fc-konjugater
DK3189074T3 (da) * 2014-09-05 2021-04-19 Rsem Lp Sammensætninger og metoder til behandling og forebyggelse af inflammation
US11007259B2 (en) 2016-01-06 2021-05-18 Order-Made Medical Research Inc. High-affinity anti-VEGF antibody
CN108779172B (zh) 2016-01-06 2022-02-08 定制药品研究株式会社 抑制vegf与nrp1结合的抗体
SG11201811559WA (en) 2016-06-27 2019-01-30 Univ California Cancer treatment combinations
JOP20190134A1 (ar) 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
CA3060514A1 (en) 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
CN110997724A (zh) * 2017-06-06 2020-04-10 斯特库伯株式会社 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
CN113226367A (zh) * 2018-04-06 2021-08-06 Atyr 医药公司 包括抗nrp2抗体的组合物和方法
JP2022514262A (ja) 2018-12-17 2022-02-10 レビトープ リミテッド 双子型免疫細胞エンゲージャー
TW202126685A (zh) 2019-09-24 2021-07-16 德商百靈佳殷格翰國際股份有限公司 抗nrp1a抗體及其用於治療眼或眼部疾病之用途
JP2022551603A (ja) 2019-10-03 2022-12-12 エータイアー ファーマ， インコーポレイテッド 抗ｎｒｐ２抗体を含む組成物および方法
GB202207116D0 (en) * 2022-05-16 2022-06-29 Quadram Inst Bioscience Method and Compositions for Tumorigenesis Inhibition
CN114949224B (zh) * 2022-06-06 2023-03-14 山东大学第二医院 Nrp2激动剂在制备复发性流产治疗药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0397834B1 (en) * 1988-10-28 2000-02-02 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US6172197B1 (en) * 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE164395T1 (de) * 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
CA2108147C (en) * 1991-04-10 2009-01-06 Angray Kang Heterodimeric receptor libraries using phagemids
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DE69233803D1 (de) 1992-10-28 2011-03-31 Genentech Inc Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten
DK0672142T3 (da) * 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
EP0971959B1 (en) 1997-04-07 2005-12-28 Genentech, Inc. Humanized antibodies and methods for forming humanized antibodies
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences

Also Published As

Publication number Publication date
US8466264B2 (en) 2013-06-18
ES2541051T3 (es) 2015-07-15
EP2158215A2 (en) 2010-03-03
AU2007353779B2 (en) 2013-11-07
US8318163B2 (en) 2012-11-27
HK1144580A1 (en) 2011-02-25
MX2009012282A (es) 2009-11-25
IL201983A (en) 2015-03-31
US20120322989A1 (en) 2012-12-20
CA2687556A1 (en) 2008-11-27
KR101523788B1 (ko) 2015-06-26
BRPI0721707A2 (pt) 2013-01-15
WO2008143666A3 (en) 2009-02-05
US20100150919A1 (en) 2010-06-17
CN101743253A (zh) 2010-06-16
JP2010530359A (ja) 2010-09-09
EP2158215B1 (en) 2015-04-22
CN101743253B (zh) 2013-05-08
WO2008143666A2 (en) 2008-11-27
IL201983A0 (en) 2010-06-16
KR20100020967A (ko) 2010-02-23
AU2007353779A1 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
RU2012109383A (ru) Кристаллические структуры фрагментов нейропилина и комплексов нейропилин-антитело
Politi et al. Role of magnesium ion in the stabilization of biogenic amorphous calcium carbonate: A structure− function investigation
Meneghini et al. Nature of “disorder” in the ordered double perovskite Sr 2 FeMoO 6
Moon et al. High pressure study of low compressibility tetracalcium aluminum carbonate hydrates 3CaO· Al2O3· CaCO3· 11H2O
Manceau et al. Structural mechanism of Co2+ oxidation by the phyllomanganate buserite
Pekov et al. The sulfite anion in ettringite-group minerals: a new mineral species hielscherite, Ca3Si (OH) 6 (SO4)(SO3)· 11H2O, and the thaumasite–hielscherite solid-solution series
Santacruz et al. Structure of stratlingite and effect of hydration methodology on microstructure
MX2009009450A (es) Anticuerpos monoclonales para he4 y metodos para su uso.
Guidobaldi et al. Multi-scale analysis of the mechanical improvement induced by lime addition on a pyroclastic soil
EA200701292A1 (ru) Композиции, содержащие антитела против рецептора igf-1, и способы получения антител
Zahid et al. Investigating the effects of solarcure curing method on the compressive strength, microstructure and polymeric reaction of fly ash based geopolymer
JP2010530359A5 (ru)
Snellings et al. The zeolite–lime pozzolanic reaction: Reaction kinetics and products by in situ synchrotron X-ray powder diffraction
Gfeller et al. The crystal structure of flamite and its relation to Ca2SiO4 polymorphs and nagelschmidtite
RU2013144545A (ru) Композиции алюмосиликатных цеолитов типа х с низким содержанием цеолита типа lta
Frost et al. Vibrational spectroscopic analysis of the mineral crandallite CaAl3 (PO4) 2 (OH) 5·(H2O) from the Jenolan Caves, Australia
Machida et al. Long-period stacking structures in yttrium trihydride at high pressure
Aufort et al. Magnesium impurities decide the structure of calcium carbonate hemihydrate
Aksenov et al. Crystal structure and topological features of manganonaujakasite, a mineral with microporous heteropolyhedral framework related to AlPO-25 (ATV)
Fois et al. High pressure deformation mechanism of Li-ABW: Synchrotron XRPD study and ab initio molecular dynamics simulations
Piro et al. Crystal and molecular structure and spectroscopic behavior of isotypic synthetic analogs of the oxalate minerals stepanovite and zhemchuzhnikovite
Miyajima et al. Niigataite, CaSrAl3 (Si2O7)(SiO4) O (OH): Sr-analogue of clinozoisite, a new member of the epidote group from the Itoigawa-Ohmi district, Niigata Prefecture, central Japan
Sugimoto et al. Chlorartinite, a volcanic exhalation product also found in industrial magnesia screed
Seryotkin et al. Structural evolution of Li-exchaned natrolite at pressure-induced over-hydration: An X-ray diffraction study
Piro et al. Crystal structure and spectroscopic behavior of synthetic novgorodovaite Ca 2 (C 2 O 4) Cl 2· 2H 2 O and its twinned triclinic heptahydrate analog

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20150513